Nowadays, viruses are not only seen as causative agents of viral infectious diseases but
also as valuable research materials for various biomedical purposes, including recombinant …

The COVID-19 pandemic has transformed vaccinology. Rapid deployment of mRNA
vaccines has saved countless lives. However, these platforms have inherent limitations …

Background As the COVID-19 pandemic continues to evolve, novel vaccines need to be
developed that are readily manufacturable and provide clinical efficacy against emerging …

IgG antibodies are important mediators of vaccine-induced immunity through complement-
and Fc receptor-dependent effector functions. Both are influenced by the composition of the …

Background SARS-CoV-2 booster vaccination should ideally enhance protection against
variants and minimise immune imprinting. This Phase I trial evaluated two vaccines targeting …

Virus-like particles (VLPs) are promising nanotools for the development of subunit vaccines
due to high immunogenicity and safety. Herein, we explored the versatile and effective …

Nanoparticle vaccines displaying mosaic receptor-binding domains (RBDs) or spike (S) from
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or other sarbecoviruses are …

Virus-like particles (VLPs) derived from bacteriophages have many applications in
biomedical sciences, especially in the development of candidate vaccines against viral and …

Supplementing influenza vaccines with additional protective antigens such as
neuraminidase (NA) is a promising strategy for increasing the breadth of the immune …

The Coronavirus Disease 2019 (COVID-19) pandemic, caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has incurred devastating human and …